Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TransCode Therapeutics, Inc. (RNAZ) is a clinical-stage RNA oncology company focused on developing therapeutics designed to overcome metastatic disease using RNA-based approaches. The company operates within the biotechnology and pharmaceutical research industries, with a specific emphasis on cancer therapeutics that leverage RNA modulation and targeted delivery technologies. Its core strategy centers on addressing metastatic cancer, which is responsible for the majority of cancer-related deaths and remains an area of significant unmet medical need.
The company’s primary revenue driver to date is research and development activities, as it does not generate product revenue and remains in the clinical development stage. TransCode’s lead product candidate, TTX‑MC138, is designed to inhibit microRNA‑10b (miR‑10b), a well-documented driver of metastatic progression across multiple solid tumors. TransCode positions itself uniquely through its proprietary nanoparticle delivery platform, which is intended to enable precise RNA delivery to tumor cells while minimizing systemic toxicity. The company was founded in 2016 and completed its initial public offering in 2021, using public market access to advance its oncology pipeline.
Business Operations
TransCode’s operations are organized around a single reportable segment focused on RNA-based oncology therapeutics, encompassing discovery, preclinical development, and clinical trials. The company generates no commercial revenue and instead funds operations primarily through equity financing, public offerings, and research grants. Its pipeline includes multiple therapeutic candidates built on its delivery technology, with development efforts concentrated on solid tumors with high metastatic potential.
The company controls a proprietary TTX nanoparticle platform, which is designed to systemically deliver RNA payloads to cancer cells. TransCode conducts research and development primarily in-house and through collaborations with academic and clinical research institutions. As of publicly available disclosures, the company does not report revenue-generating subsidiaries or commercial joint ventures; its operations are centered on advancing clinical trials and maintaining its intellectual property portfolio. Data on material long-term commercial partnerships is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, TransCode is focused on advancing TTX‑MC138 through clinical development while expanding its pipeline of RNA-targeted cancer therapeutics. Growth initiatives include progressing clinical trials, generating human efficacy and safety data, and potentially broadening indications for its lead candidate across multiple tumor types. The company has also disclosed development programs targeting other RNA molecules implicated in cancer progression and drug resistance.
Investment activity is primarily directed toward internal research and development rather than external acquisitions. As of the most recent public disclosures, TransCode has not completed any transformative mergers or acquisitions and does not maintain a diversified portfolio of operating subsidiaries. Its long-term strategic positioning relies on validating its delivery platform and establishing clinical proof-of-concept that could support future licensing, partnership, or acquisition opportunities. Information regarding late-stage strategic partnerships remains inconclusive based on available public sources.
Geographic Footprint
TransCode Therapeutics is headquartered in Massachusetts, within the Greater Boston/Cambridge biotechnology hub, a region known for dense concentration of life sciences research, clinical institutions, and capital markets access. The company’s executive leadership, research oversight, and corporate functions are primarily based in this region.
Operationally, TransCode’s activities are largely U.S.-focused, with clinical trials and research conducted in collaboration with domestic and select international clinical sites. While the company does not maintain extensive physical operations outside the United States, its clinical development strategy involves engagement with global regulatory standards and potential international trial participation. Data on permanent international offices or subsidiaries is inconclusive based on available public sources.
Leadership & Governance
TransCode was founded by scientific leadership with expertise in RNA biology and cancer research, and its governance structure reflects a research-driven strategic vision focused on addressing metastatic disease. The leadership philosophy emphasizes translational science, disciplined capital allocation, and leveraging academic innovation to advance clinical programs.
Key executives include:
- Anna C. Moore – President and Chief Executive Officer
- Zdravka Medarova, Ph.D. – Co‑Founder and Chief Scientific Officer
- Paul V. Lee – Chief Financial Officer
- Erin C. McKiernan – Chief Operating Officer
The board of directors includes individuals with backgrounds in biotechnology, finance, and oncology drug development, providing oversight aligned with the company’s long-term clinical and strategic objectives.